When are beta‑blockers indicated in aortic stenosis and aortic regurgitation, and how should they be started and titrated?

Beta-Blockers in Aortic Stenosis and Aortic Regurgitation

Beta-blockers are appropriate in aortic stenosis when patients have reduced ejection fraction, prior MI, arrhythmias, or angina, but should generally be avoided in chronic aortic regurgitation due to theoretical concerns about prolonging diastolic filling time and worsening regurgitant volume. 1, 2

Aortic Stenosis: When to Use Beta-Blockers

Primary Indications

Beta-blockers are specifically indicated in patients with aortic stenosis who have: 1, 2

• Reduced ejection fraction (heart failure with reduced LVEF)
• Prior myocardial infarction
• Cardiac arrhythmias (including atrial fibrillation)
• Angina pectoris

Evidence Supporting Use

• In the SEAS study, patients already receiving beta-blockers at baseline demonstrated a 23% reduction in cardiovascular events 3
• A post-hoc analysis of 1,873 asymptomatic patients with mild-to-moderate AS showed beta-blocker use was associated with lower all-cause mortality (HR 0.5), cardiovascular death (HR 0.4), and sudden cardiac death (HR 0.2) 4
• Metoprolol reduces valve gradients and myocardial oxygen consumption in asymptomatic moderate-severe AS 3

Starting and Titrating in AS

Start low and go slow: 1, 2

• Begin with low doses of beta-blockers
• Gradually titrate upward as tolerated
• Monitor for hypotension, particularly in patients with severe AS
• In patients with moderate or severe AS, cardiology consultation or co-management is preferred for overall hypertension management 1, 2

Important Caveats

The 2017 ACC/AHA guidelines emphasize that there is no evidence that antihypertensive medications produce an inordinate degree of hypotension in patients with aortic stenosis 1, 2. This dispels the traditional fear of using these agents in AS patients.

Aortic Regurgitation: Avoid Beta-Blockers

Primary Recommendation

In patients with chronic aortic insufficiency, treatment of systolic hypertension with agents that do not slow the heart rate (i.e., avoid beta-blockers) is reasonable (Class IIa, Level C-LD). 1, 2

Physiologic Rationale

Beta-blockers may result in: 1, 2

• Increased diastolic filling period due to bradycardia
• Potentially increased aortic insufficiency (more time for regurgitation per cardiac cycle)
• Marked reduction in diastolic BP may lower coronary perfusion pressure in chronic severe AR

Important Nuance

However, there are no outcomes data to support these theoretical concerns. 1, 2 In fact, one observational study of 756 patients with severe AR showed that beta-blocker therapy was associated with higher survival rates (1-year: 90% vs 75%; 5-year: 70% vs 55%) and was an independent predictor of better survival (HR 0.74) 5. Additionally, beta-blocker therapy after aortic valve replacement for AR may improve cardiac performance by reducing cardiac volume and mass 6.

Preferred Agents in AR

For hypertension management in AR, prefer: 1, 2

• ACE inhibitors or ARBs (RAS blockade)
• Dihydropyridine calcium channel blockers
• These agents provide vasodilation without slowing heart rate

Special Populations

In patients with Marfan syndrome and aortic root dilation, beta-blockers are specifically recommended to slow progression of aortic dilatation, even in the presence of AR, though they should be used cautiously in severe AR 7

Practical Algorithm

For AS Patients:

1. Assess for specific indications: reduced EF, prior MI, arrhythmias, angina
2. If present: Start beta-blocker at low dose, titrate gradually
3. If absent but hypertensive: Prefer RAS inhibitors first-line 1, 2
4. Involve cardiology for moderate-severe AS 1

For AR Patients:

1. Default position: Avoid beta-blockers 1, 2
2. Use instead: ACE inhibitors, ARBs, or dihydropyridine CCBs
3. Exception: Marfan syndrome with aortic root disease 7
4. Post-AVR: Beta-blockers may be beneficial for LV remodeling 6

Common Pitfalls to Avoid

• Don't withhold beta-blockers in AS patients with clear indications (HFrEF, post-MI, arrhythmias) due to outdated fears about hypotension 1, 4
• Don't use calcium channel blockers or alpha-blockers as first-line in AS with hypertension—CCBs were associated with sevenfold increase in mortality in one study 3
• Don't use diuretics aggressively in AS patients with small LV chamber dimensions 1, 2
• Don't assume beta-blockers are absolutely contraindicated in AR—the theoretical concerns lack outcomes data support, and observational data suggest potential benefit 1, 5